


INAJOG

Indonesian
Journal of
Obstetrics and
Gynecology

Volume: 6, No. 1, page 1 - 68 January 2018

Founded 1974



IMPOSING A SIGNIFICANT BURDEN ON WOMEN
WHO HAVE THEM

Editorial

Stress Urinary Incontinence (SUI): Conservative and Surgical Approach 2

Research Articles

- Effectiveness of Oral Probiotics (*Lactobacillus Rhamnosus* Gr-1 and *Lactobacillus Reuteri* RC-14) as Adjuvant Therapy in Reproductive Aged Women with Vaginal Discharge 3
- The Association between Menstrual Disorder and Work Disturbance among Employees 10
- The Association of C-Reactive Protein Levels in Second Trimester of Pregnancy with Preeclampsia 18
- Relationship between Vaginal Sialidase Levels with Threatened of Preterm Labour 23
- Internet Based Infertility Information in Bahasa Indonesia Quality Survey 28
- Pregnancy Outcome in Infertility Patient with Endometriosis Cyst after Laparoscopic Cystectomy 34
- Relationship between Knowledge, Attitude and Behavior of Postnatal Woman Toward Participation in Permanent Contraception 39
- A Comparative Study of Nomegestrol Acetate and a Combination of Ethinylestradiol and Levonorgestrel for Delaying Menstruation among Umrah Pilgrims 45
- L-selectin Levels in Patients with Endometriosis 50
- Obstetric Risk Factors and Anal Incontinence among Women with Previous History of Vaginal Delivery 55
- Incidence of Pelvic and Paraaortic Lymph Node Metastasis in Epithelial Ovarian Cancer at a Tertiary Care Center 60
- The Effect of Cyclophosphamide Chemotherapy on Ovarian Anti-Müllerian Hormone Levels in Breast Cancer Patients 64



Official Publication of
Indonesian Society of Obstetrics and Gynecology

www.inajog.com

Accredited (2014 - 2019)

by the Directorate General of Higher Education of the Ministry of Education and Culture of the Republic of Indonesia

No.: 212/P/2014, 3 Juli 2014

INDONESIAN JOURNAL OF OBSTETRICS AND GYNECOLOGY

Indones J Obstet Gynecol

Majalah Obstetri dan Ginekologi Indonesia

CONTENT

Volume 6, Number 1, Page 1 - 68, January 2018

Editorial

- Budi I. Santoso 2 **Stress Urinary Incontinence (SUI): Conservative and Surgical Approach**
Jakarta

Research Articles

- Junita Indarti 3 **Effectiveness of Oral Probiotics (Lactobacillus Rhamnosus Gr 1 and Lactobacillus Reuteri RC 14) as Adjuvant Therapy in Reproductive Aged Women with Vaginal Discharge**
Utomo Budidarmo
Jakarta
There was no clinical and statistical difference in the proportion of cure rate and the level of satisfaction in patients of probiotics vs placebo groups after treatment for 4 weeks. The initial hypothesis of higher proportion of the cure rate in the treatment group still cannot be excluded, due to insufficient samples.
- I.P.G. Kayika 10 **The Association between Menstrual Disorder and Work Disturbance among Employees**
Iftikar Abdullah
Gita Pratama
Laila Nuranna
Jakarta
The prevalence of severe work disturbance due to menstruation is not high but can lead to disruption in running jobs and activities. However, it is important to be a concern so that the employees get good management and care.
- Zulfaekasari Nasruddin 18 **The Association of C Reactive Protein Levels in Second Trimester of Pregnancy with Preeclampsia**
Efendi Lukas
Umar Malinta
Maisuri T. Chalid
Makassar
The average score of C-Reactive protein of preeclampsia group is 33.5% higher than non-preeclampsia group, even though these results cannot be used as the score to predict the preeclampsia occurrence.
- Bambang Sulistyono 23 **Relationship between Vaginal Sialidase Levels with Threatened of Preterm Labour**
Najoan N. Warouw
Eddy Suparman
Manado
There is a relationship between the incidence threatened of preterm labor with vaginal sialidase levels.
- Andon Hestiantoro 28 **Internet Based Infertility Information in Bahasa Indonesia Quality Survey**
Intan Kusumaningtyas
Jakarta
The quality of internet based infertility information in Bahasa is adequate for category credibility, accuracy and ease of navigation.
- Eka R. Gunardi 34 **Pregnancy Outcome in Infertility Patient with Endometriosis Cyst after Laparoscopic Cystectomy**
Duta A. Tritama
Luky Satria
Herbert Situmorang
Jakarta
The pregnancy rate after laparoscopic procedure is 35,9% in this study. There are correlation between age, duration of infertility, and r-AFS staging with pregnancy rate.
- Jhon Heriansyah 39 **Relationship between Knowledge, Attitude and Behavior of Postnatal Woman Toward Participation in Permanent Contraception**
Azhari
Firmansyah Basir
Theodorius
Palembang
Factors that influence the participation of women in RSMH safe contraception Palembang include support for her husband and behavior.
- Mirzah Tindar 45 **A Comparative Study of Nomegestrol Acetate and a Combination of Ethinylestradiol and Levonorgestrel for Delaying Menstruation among Umrah Pilgrims**
Yusuf Effendi
Adenan Abadi
Theodorius
Palembang
There is no difference in effectiveness between nomegestrol acetate 5 mg or combination of levonorgestrel 150 mcg and 30 mcg ethinylestradiol as a regimen for delaying menses in Umrah pilgrims in Palembang city.
- Melkiandri Fanggalda 50 **L selectin Levels in Patients with Endometriosis**
Maria F.T. Loho
Maya E. Mewengkang
Manado
L-selectin levels in women with endometriosis increased according to clinical stage, but not significant in statistical tests. There is no significant relationship between age with stages or levels of L-selectin in women with endometriosis.
- Azizah Nurdin 55 **Obstetric Risk Factors and Anal Incontinence among Women with Previous History of Vaginal Delivery**
Trika Irianta
Mardiah Tahir
Maisuri T. Chalid
Makassar
Parity, vacuum delivery and prolong second stage of labor have an association with anal incontinence among women who has history of vaginal delivery
- Andrijono 60 **Incidence of Pelvic and Paraortic Lymph Node Metastasis in Epithelial Ovarian Cancer at a Tertiary Care Center**
Risa Risfiandi
Jakarta
Lymph node metastasis incident of ovarian epithelial cancer in paraaorta amounts 20%, pelvic 9.1% and pelvic or paraaortic 23.6%. Higher the stadium, the lymph node involvements will be higher as well (pelvic and paraaortic). In stadium 1 of mucinous subtype with well differentiation has minimal lymph node involvement so we can be more selective in considering the risk and benefit of lymphadenectomy.
- Elisabeth G.K. Liga 64 **The Effect of Cyclophosphamide Chemotherapy on Ovarian Anti Müllerian Hormone Levels in Breast Cancer Patients**
Nusratuddin Abdullah
Eddy Tiro
Maisuri T. Chalid
Makassar
AMH levels decreased significant after cyclophosphamide indicated that cyclophosphamide decrease ovarian reserve.

Research Article

The Effect of Cyclophosphamide Chemotherapy on Ovarian Anti Müllerian Hormone Levels in Breast Cancer Patients***Efek Kemoterapi Siklofosfamid terhadap Kadar Hormon Anti Müllerian Ovarium pada Penderita Kanker Payudara***

Elisabeth G.K. Liga, Nusratuddin Abdullah, Eddy Tiro, St. Maisuri T. Chalid

*Department of Obstetrics and Gynecology
Faculty of Medicine Universitas Hasanuddin/
Dr. Wahidin Sudirohusodo Hospital
Makassar***Abstract****Objective:** To evaluate cyclophosphamide effects on Anti-Müllerian hormone (AMH) levels in breast cancer patients treated with cyclophosphamide chemotherapy.**Methods:** This cohort prospective study was conducted in Dr. Wahidin Sudirohusodo Hospital in the Department of Obstetrics and Gynecology in collaboration with Department of Surgery, Faculty of Medicine, Universitas Hasanuddin between September 2015 and June 2016. Serum levels of AMH from forty breast cancer patients received three series of cyclophosphamide chemotherapy determined by Enzyme Linked Immuno Sorbent Assay (ELISA).**Results:** Serum AMH levels decreased significant in the first series (from 2.09 ± 2.04 $\mu\text{g/ml}$ to 0.65 ± 1.06 $\mu\text{g/ml}$; $p < 0.05$) through the third series (from 1.53 ± 1.34 $\mu\text{g/ml}$ to 0.5 ± 0.65 $\mu\text{g/ml}$; $p < 0.05$) of cyclophosphamide chemotherapy.**Conclusion:** AMH levels decreased significant after cyclophosphamide indicated that cyclophosphamide decrease ovarian reserve.

[Indones J Obstet Gynecol 2018; 6-1: 64-67]

Keywords: anti-müllerian hormone, breast cancer, cyclophosphamide, ovarian reserve**Abstrak****Tujuan:** Menilai efek kemoterapi siklofosfamid terhadap kadar hormon Anti-Müllerian pada pasien kanker payudara yang dikemoterapi dengan siklofosfamid.**Metode:** Penelitian kohort prospektif ini dilakukan di RS Dr. Wahidin Sudirohusodo pada Departemen Obstetri dan Ginekologi bekerjasama dengan Departemen Bedah, Fakultas Kedokteran, Universitas Hasanuddin antara September 2015 dan Juni 2016. Pengukuran kadar serum AMH dari 40 pasien kanker yang mendapatkan tiga seri kemoterapi siklofosfamid menggunakan metode Enzyme Linked Immuno Sorbent Assay (ELISA).**Hasil:** Kadar serum AMH menurun signifikan dari seri pertama (dari $2,09 \pm 2,04$ $\mu\text{g/ml}$ menjadi $0,65 \pm 1,06$ $\mu\text{g/ml}$; $p < 0,05$) sampai seri ketiga (dari $1,53 \pm 1,34$ $\mu\text{g/ml}$ menjadi $0,5 \pm 0,65$ $\mu\text{g/ml}$; $p < 0,05$) pada kemoterapi dengan siklofosfamid.**Kesimpulan:** Kadar AMH menurun signifikan setelah kemoterapi siklofosfamid menunjukkan siklofosfamid menurunkan cadangan ovarium.

[Maj Obstet Ginekol Indones 2018; 6-1: 64-67]

Kata kunci: anti-müllerian hormon, cadangan ovarium, hormon, kanker payudara, siklofosfamid**Correspondence:** Elisabeth GK Liga, Department titha_liga@yahoo.co.id**INTRODUCTION**

Breast cancer is the most frequency malignancy in women in developed countries. It is estimated that approximately 7% of women with breast cancer are diagnosed before the age of 40 years, and this disease accounts for more than 40% of all cancer in women in this age group.¹ Breast cancer is likely to have a negative impact on reproductive function from the toxic effect of chemotherapy on ovarian follicles.² Young women with more primordial oocytes showed a significant reduction of their ovarian reserve following chemotherapy.³ Chemotherapy causes acute loss of growing follicles

resulting in premature ovarian failure, shortened reproductive life span and hormone deficiency.^{4,5}

Cyclophosphamide, also known as cytophosphane, is a nitrogen mustard alkylating agent from the oxazophorine group. Cyclophosphamide is used to treat various types of cancer and some autoimmune disorders by slowing-down or stopping cell growth.⁶ Cyclophosphamide, alone or in combination with other chemotherapy agents, is used for the treatment of lymphomas, some forms of leukemia, and some types of solid tumours including breast cancer. Gonadal failure is a major complication of cyclophosphamide administration,

especially in females.⁷ Cyclophosphamide affects primordial follicle density rapidly after injection of this agent. Human oocytes are damaged drastically followed by granulosa cells.⁸

The granulosa cells of primary follicles produced Anti-Müllerian Hormone (AMH).^{9,15} AMH is a glycoprotein hormone belonging to transforming growth factor b family. It's levels reflect the continuous non-cyclical growth of small follicles.¹⁰ Women with abnormal level of this hormone impaired the ovarian reserved followed by fertility.¹¹ This study aimed to evaluate the levels of AMH in breast cancer patients treated with cyclophosphamide chemotherapy.

METHODS

This cohort prospective study was conducted in Dr. Wahidin Sudirohusodo Hospital in the Department of Obstetrics and Gynecology in collaboration with Department of Surgery, Faculty of Medicine, Universitas Hasanuddin between September 2015 and June 2016. The study protocol was approved by the Health Research Ethics Committee of Faculty of Medicine, Universitas Hasanuddin. Eligible patients were women with breast cancer, aged 20 to 48 years, who were to receive three series of cyclophosphamide treatment but who had not received chemotherapy previously. Prior chemotherapy, radiation therapy, oophorectomy, and patients who did not complete the first series of chemotherapy cycles until the third series were ineligible. Serum levels of AMH in each series of chemotherapy were measured at Prodia Clinical Laboratory Jakarta using AMH Enzyme Linked Immuno Sorbent Assay (ELISA) kits. Statistical analysis was performed using SPSS. A two-sided p value <.05 was considered statistically significant.

RESULTS

The study included 40 women with breast cancer who completed the three series of cyclophos-

phamide chemotherapy. Table 1 summarizes the characteristics of the patients. Seventy percent of the patients were aged 36-47 years, 52.5% had senior high school education, majority of patients had married (87.5%) and multiparity (51.4%).

Table 1. Subject characteristics

Variables	n	%
Age (years)		
29 - 35	12	30.0
36 - 47	28	70.0
Education		
SMP	12	30.0
SMA	21	52.5
College	7	17.5
Marital status		
Married	35	87.5
Unmarried	5	12.5
Parity		
0	3	8.6
1 - 2	14	40.0
> 2	18	51.4

Decreased serum AMH levels were seen after each series of cyclophosphamide chemotherapy; first series from 2.09±2.04 µg/ml to 0.65±1.06 µg/ml, second series from 4.03±3.47 µg/ml to 1.30±1.40 and third series from 1.53±1.34 to 0.50±0.65 µg/ml. There was an overall significant decrease in serum AMH levels (p<0.05) for the three series of chemotherapy (Table 2).

DISCUSSION

In reproductive-aged women treated with chemotherapy and radiotherapy for malignancy, serum AMH levels could be used to predict the ovarian

Table 2. AMH Levels in the Series of Cyclophosphamide Chemotherapy of Breast Cancer

Series of chemotherapy	AMH levels (mean±SD µg/ml)		p
	Prechemotherapy	Postchemotherapy	
First	2.09±2.04	0.65±1.06	0.000
Second	4.03±3.47	1.30±1.40	0.003
Third	1.53±1.34	0.50±0.65	0.010

reserve.¹² Chemotherapy has a negative effect on the ovarium that cause the loss of primordial follicles, thus the levels of serum AMH as a marker for early prediction of the ovarian reserve.¹³

We found that there was a significant decrease in serum AMH levels in breast cancer patient treated with cyclophosphamide in the present study. AMH and inhibin B levels immediately decreased after chemotherapy.¹⁴ AMH hormone is produced predominantly in primary, preantral, and small antral follicles.¹⁵ The growing follicles appeared to be the target of chemotherapy agents.¹⁴ Anders et al. conducted a study in AMH, E2, FSH, inhibin B, and AFC for markers of ovarian reserve in patients who received adjuvant treatment. They observed significantly decreased or undetectable serum AMH levels after chemotherapy similar to other previous studies.¹⁶

This study also found that AMH levels decreased after the first series and along with the next series of chemotherapy. Our results similar to previous study on breast cancer treated with cyclophosphamide that serum AMH levels decreased from first series (2.7 ± 1.0 ng/ml) to second series (0.4 ± 0.4 ng/ml).¹⁴ Another study also assayed AMH and other hormonal markers before, during and after chemotherapy administration and reported the decreased serum AMH levels after chemotherapy indicating direct chemotherapy induced damage to the granulosa cells and hence growing follicles and ultimately the follicle pool resulting in decreased ovarian reserve.¹⁷

AMH levels differ among breast cancer patients that received chemotherapy due to dose administration. Study found that difference dose correlated with AMH levels 0.52 ng/ml, 1.99 ng/ml and 3.09 ng/ml in high dose, low dose and not exposed to chemotherapy, respectively. Increased dose of chemotherapy has greater reduction in AMH levels (Gracia et al., 2012).¹⁸

AMH levels variations before, during and after chemotherapy provide information about the degree of follicle loss for each patient according to different chemotherapy regimens. Different patterns of AMH levels during the ovarian recovery phase make it possible to discriminate between high and low gonadotoxic chemotherapy protocols. In addition, pretreatment AMH levels are shown to predict the long-term ovarian function after the end of treatment. These provide a better understanding on the ovarian toxicity mechanisms of

chemotherapy and to predict the degree of the ovarian follicle loss. Therefore, it can be useful for fertility preservation strategies, fertility counseling and future family planning.¹⁹

CONCLUSION

AMH levels decreased significant after cyclophosphamide chemotherapy. This is indicated that cyclophosphamide decreased ovarian reserve.

REFERENCES

1. Anders CK, Johnson R, Litton J, et al. Breast Cancer Before Age 40 Years. *Semin Oncol.* 2009; 36(3): 237-49.
2. Hickey M, Peate M, Saunders CM, Friedlander M. Breast cancer in young women and its impact on reproductive function. *Hum Reprod Update* 2009; 15: 32-9.
3. Partridge AH, Ruddy KJ, Gelber S, et al. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. *Fertil Steril.* 2010; 94: 638-44.
4. Meirou D, Biederman H, Anderson RA, Wallace WH. Toxicity of chemotherapy and radiation on female reproduction. *Clin Obstet Gynecol.* 2010; 53: 727-39.
5. Oktem O, Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. *Cancer.* 2007; 110: 2222-9.
6. Chen L, Waxman DJ, Chen D, Kufe DW. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene1. *Cancer Res.* 1996; 56: 1331-40.
7. Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. *Nat Rev Clin Oncol.* 2009; 6(11): 638-47.
8. Oktem O, Oktay K. A novel ovarian xenografting model to characterize the impact of chemotherapy agents on human primordial follicle reserve. *Cancer Res.* 2007; 67(21): 10159-62.
9. Massague' J. The transforming growth factor-beta family. *Annu Rev Cell Biol.* 1990; 6: 597-641.
10. Anderson RA. What does anti-Müllerian hormone tell you about ovarian function? *Clin Endocrinol.* 2012; 77(5): 652-5.
11. Iverson A, Younis A, William J, et al. Inverse Correspondence of AMH and FSH levels in Women Presenting for Infertility Treatment. *J South Carolina Academy Sci.* 2011; 9(2): 1-4.
12. Anderson CY, Rosendahl M, Byskov AG, et al. Two successful pregnancies following autotransplantation of frozen/thawed ovarian tissue. *Hum Reprod* 2008; 23: 2266-72.
13. Steiner AZ, Stanczyk FZ, Patel S, Edelman A. Anti mullerian hormone and obesity: insights in oral contraceptive users. *Contracept.* 2010; 81(3): 245-8.
14. Rosendahl M, Andersen CY, la Cour Freiesleben N, et al. Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age. *Fertil Steril* 2010; 94(1): 156-66.

15. Durlinger AL, Visser JA, Themmen AP. Regulation of ovarian function: the role of anti-Müllerian hormone. *Reprod.* 2002; 124: 601-9.
16. Anders C, Marcom PK, Peterson B, et al. A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer. *Cancer Invest.* 2008; 26(3): 286-95.
17. Visser JA, de Jong FH, Laven JS, Themmen AP. Anti-Müllerian hormone: a new marker for ovarian function. *Reprod.* 2006; 131(1): 1-9.
18. Gracia CR, Sammel MD, Freeman E, et al. Impact of cancer therapies on ovarian reserve. *Fertil Steril.* 2012; 97(1): 134-40.
19. Paigne M, Decanter C. Serum AMH level as a marker of acute and long-term effects of chemotherapy on the ovarian follicular content: a systematic review. *Reprod Biol Endocrinol.* 2014; 12: 26.